RJA
RDY icon

Raymond James & Associates’s Dr. Reddy's Laboratories RDY Stock Holding History

Raymond James & Associates’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-90,810
Closed -$682K – 3568
2017
Q4 		$682K Sell
90,810
-22,830
-20% -$164K ﹤0.01% 2358
2017
Q3 		$811K Buy
+113,640
New +$817K ﹤0.01% 2220
2017
Q1 		– Sell
-33,710
Closed -$305K – 3382
2016
Q4 		$305K Sell
33,710
-8,530
-20% -$79.4K ﹤0.01% 2615
2016
Q3 		$392K Buy
+42,240
New +$403K ﹤0.01% 2439

Other funds holding RDY

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $355M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Raymond James & Associates's RDY Position: Q1 2018 in Review

Raymond James & Associates sold out of Dr. Reddy's Laboratories (RDY) in Q1 2018, closing a stake of 90,810 shares — an estimated $682K sold.

Raymond James & Associates first reported a position in RDY in Q3 2016 and held it in 4 quarters. The position peaked at $811K in Q3 2017. 121 funds tracked by Wall St. Rank hold RDY as of Q1 2018.

  • Raymond James & Associates reported no remaining Dr. Reddy's Laboratories position as of Q1 2018 after selling out during the quarter.
  • Raymond James & Associates sold 90,810 Dr. Reddy's Laboratories shares in Q1 2018, an estimated $682K.
  • Raymond James & Associates first reported a position in Dr. Reddy's Laboratories in Q3 2016 and held it in 4 quarters.
  • Raymond James & Associates's Dr. Reddy's Laboratories position peaked at $811K in Q3 2017.
  • 121 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2018.

Based on Raymond James & Associates's 13F filing for Q1 2018, filed 14 May 2018.